Your browser doesn't support javascript.
E-cigarettes to Augment Stop Smoking In-person Support and Treatment with varenicline (E-ASSIST): a pragmatic randomised controlled trial.
Tattan-Birch, Harry; Kock, Loren; Brown, Jamie; Beard, Emma; Bauld, Linda; West, Robert; Shahab, Lion.
  • Tattan-Birch H; Department of Behavioural Science and Health, University College London, London, UK.
  • Kock L; SPECTRUM Consortium, UK.
  • Brown J; Department of Behavioural Science and Health, University College London, London, UK.
  • Beard E; SPECTRUM Consortium, UK.
  • Bauld L; Department of Behavioural Science and Health, University College London, London, UK.
  • West R; SPECTRUM Consortium, UK.
  • Shahab L; Department of Behavioural Science and Health, University College London, London, UK.
Nicotine Tob Res ; 2022 Jun 23.
Article in English | MEDLINE | ID: covidwho-2236169
ABSTRACT

BACKGROUND:

We examined whether, in adults receiving behavioural support, offering e-cigarettes together with varenicline helps more people stop smoking cigarettes than varenicline alone.

METHODS:

A two-group, parallel-arm, pragmatic randomised controlled trial was conducted in six English stop smoking services from 2019-2020. Adults enrolled onto a 12-week programme of in-person one-to-one behavioural smoking cessation support (N=92) were randomised to receive either (i) a nicotine e-cigarette starter-kit alongside varenicline or (ii) varenicline alone. The primary outcome was biochemically-verified abstinence from cigarette smoking between weeks nine-to-12 post quit-date, with those lost to follow-up considered not abstinent. The trial was stopped early due to COVID-19 restrictions and a varenicline recall (92/1266 participants recruited).

RESULTS:

Nine-to-12-week smoking abstinence rates were 47.9% (23/48) in the e-cigarette-varenicline group compared with 31.8% (14/44) in the varenicline-only group, a 51% increase in abstinence among those offered e-cigarettes; however, the confidence interval (CI) was wide, including the possibility of no difference (risk ratio [RR]=1.51, 95%CI=0.91-2.64). The e-cigarette-varenicline group had 43% lower hazards of relapse from continuous abstinence than the varenicline-only group (hazards ratio [HR]=0.57, 95%CI=0.34-0.96). Attendance for 12 weeks was higher in the e-cigarette-varenicline than varenicline-only group (54.2% versus 36.4%; RR=1.49, 95%CI=0.95-2.47), but similar proportions of participants in both groups used varenicline daily for ≥8 weeks after quitting (22.9% versus 22.7%; RR=1.01, 95%CI=0.47-2.20). Estimates were too imprecise to determine how adverse events differed by group.

CONCLUSION:

Tentative evidence suggests offering e-cigarettes alongside varenicline to people receiving behavioural support may be more effective for smoking cessation than varenicline alone. IMPLICATIONS Offering e-cigarettes to people quitting smoking with varenicline may help them remain abstinent from cigarettes, but the evidence is tentative because our sample size was smaller than planned - caused by COVID-19 restrictions and a manufacturing recall. This meant our effect estimates were imprecise, and additional evidence is needed to confirm that providing e-cigarettes and varenicline together helps more people remain abstinent than varenicline alone.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Prognostic study / Randomized controlled trials Language: English Journal subject: Public Health Year: 2022 Document Type: Article Affiliation country: Ntr

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Prognostic study / Randomized controlled trials Language: English Journal subject: Public Health Year: 2022 Document Type: Article Affiliation country: Ntr